Depomed Named to Deloitte's Technology Fast 500™ List of Fastest Growing Companies in North America

NEWARK, Calif., Nov. 16, 2016 -- Depomed, Inc. (NASDAQ:DEPO), a leading pharmaceutical company focused on central nervous system conditions including pain, today announced that it has been named to Deloitte's 2016 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences, and energy technology companies in North America. Rankings are based on percentage revenue growth from 2012 to 2015, during which Depomed experienced a 1186% growth.

"We are honored once again to be recognized for our exceptional growth and part of the list with such a highly-distinguished group,” said Jim Schoeneck, President and CEO of Depomed. “We are proud to have built one of the highest growth companies in the pharmaceutical industry, serving patients with our differentiated pain and nervous system portfolio.”

 “Today, when every organization can be a tech company, the most effective businesses not only foster the courage to explore change, but also encourage creativity in using and applying existing assets in new ways, as resourcefully as possible,” said Sandra Shirai, principal, Deloitte Consulting LLP and U.S. technology, media and telecommunications industry leader. “This ingenious approach to innovation calls for the encouragement of curiosity and collaboration both within and outside the office walls.”

 “This year’s Fast 500 winners showcase that when organizations are open to diverse perspectives and insights, they are able to create an environment for their employees and customers to see the possibilities and ingenious solutions that might lie ahead,” added Jim Atwell, national managing partner of the emerging growth company practice, Deloitte & Touche LLP. “Entrepreneurial environments foster change and innovation within businesses, and we look forward to watching these companies continue to drive change across all sectors.” 

About Deloitte's 2016 Technology Fast 500™

Deloitte's Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2012 to 2015.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years and be headquartered within North America.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.

INVESTOR CONTACT:

Christopher Keenan
VP, Investor Relations and Corporate Communications
Depomed, Inc.
510-744-8000
[email protected]